The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Towards a personalized treatment approach for SCD
Raffaella Colombatti, MD, PhD, University of Padova, Padova, Italy, discusses personalized treatment in sickle cell disease (SCD), highlighting the importance of better understanding the biology of SCD and of finding novel biomarkers to eventually allow patients to achieve a quality of life (QoL) comparable to that of healthy individuals. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
